Erythromycin
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1964
- First approval year
- 1964
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Erythromycin
- Molecular weight
- 733.94
- Structure (SMILES)
- CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
- a t s
- A/t/s
- akne mycin
- Akne-mycin
- aknemycin plus
- Aknemycin plus
- c solve 2
- C-solve-2
- e base
- e glades
- e mycin
- e solve 2
- E-base
- E-glades
- E-mycin
- E-solve 2
- emgel
- Emgel
- ery tab
- Ery-tab
- eryacne 2
- Eryacne 2
- eryacne 4
- Eryacne 4
- eryc
And 63 more, listed on the interactive page.
- benzamycin component erythromycin
- BENZAMYCIN COMPONENT ERYTHROMYCIN
- eritromicina
- Eritromicina
- erythromycin
- Erythromycin
- ERYTHROMYCIN [EP MONOGRAPH]
- ERYTHROMYCIN [GREEN BOOK]
- ERYTHROMYCIN [HSDB]
- erythromycin [INN]
- ERYTHROMYCIN [JAN]
- ERYTHROMYCIN [MART.]
- ERYTHROMYCIN [MI]
- ERYTHROMYCIN [ORANGE BOOK]
- ERYTHROMYCIN [USP MONOGRAPH]
- ERYTHROMYCIN [USP-RS]
- ERYTHROMYCIN [VANDF]
- Erythromycin [WHO-DD]
- ERYTHROMYCIN [WHO-IP]
- erythromycin a
- ERYTHROMYCIN A
- erythromycin ep monograph
- erythromycin estolate impurity free erythromycin
- erythromycin estolate impurity free erythromycin ep impurity
- erythromycin estolate impurity free erythromycin usp impurity
And 33 more, listed on the interactive page.
- CAS registry numbers
- 114-07-8
- ChEMBL ID
- CHEMBL532
- InChIKey
- ULGZDMOVFRHVEP-RWJQBGPGSA-N
- PubChem compound IDs
- 12560
- FDA ingredient codes (UNII)
- 63937KV33D
- D10AF02
- D10AF52
- J01FA01
- S01AA17
Sources for recorded values
- 4053
- 24351
- Applicant
- DR REDDYS LABS SA
- Approval date
- 26 Jan 1981
- Application number
- NDA050536
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- Pharmacology name
- erythromycin
- Type
- Natural product
- Drug name stem
- -mycin
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Parenteral
- topical
- Action
- Full agonist
- Action type
- FULL_AGONIST
- Target
- motilin receptor
- Gene symbol
- MLNR
- Protein identifier
- O43193
- Affinity units
- pIC50
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P02358
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P02359
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P02413
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7J3
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7J7
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7K2
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7K6
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7L0
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7L3
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7L8
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7M2
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7M6
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7M9
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7N1
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7N4
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7N9
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7P5
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7Q1
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7Q6
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7R5
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7R9
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7S3
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Protein identifier
- P0A7S9
And 32 more, listed on the interactive page.
Open Targets mechanisms
- Mechanism
- Bacterial 70S ribosome inhibitor
- Action type
- Inhibitor
- Target
- Bacterial 70S ribosome
- Condition
- Leukemia, Lymphocytic, Chronic, B-Cell
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000095
- Subject identifier
- D015451
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000365
- Subject identifier
- D015179
- Condition
- Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Whooping Cough
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000650
- Subject identifier
- D014917
- Condition
- HIV Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition
- Bacterial Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000771
- Subject identifier
- D001424
- Condition
- Hepatitis C
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003047
- Subject identifier
- D006526
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Osteomyelitis
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0003102
- Subject identifier
- D010019
- Condition
- Pneumonia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003106
- Subject identifier
- D011014
- Condition
- Acne Vulgaris
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003894
- Subject identifier
- D000152
- Condition
- Erectile Dysfunction
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004234
- Subject identifier
- D007172
- Condition
- Feeding and Eating Disorders
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005203
- Subject identifier
- D001068
- Condition
- Bulimia Nervosa
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005204
- Subject identifier
- D052018
- Condition
- Chlamydia Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007205
- Subject identifier
- D002690
- Condition
- Epidermolysis Bullosa
- Highest recorded phase
- 3
- Condition identifier
- EFO:1000690
- Subject identifier
- D004820
- Condition
- Gastroparesis
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000948
- Subject identifier
- D018589
- Condition
- Eye Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:1001888
- Subject identifier
- D015817
- Condition
- Renal Insufficiency
- Highest recorded phase
- 1
- Condition identifier
- HP:0000083
- Subject identifier
- D051437
- Condition
- Gastrointestinal Hemorrhage
- Highest recorded phase
- 3
- Condition identifier
- HP:0002239
- Subject identifier
- D006471
- Condition
- Hematemesis
- Highest recorded phase
- 3
- Condition identifier
- HP:0002248
- Subject identifier
- D006396
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0001056
- Subject identifier
- D013274
- Condition identifier
- EFO_0000095
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000341
- Condition identifier
- EFO_0000365
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000544
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 4
- Condition identifier
- EFO_0000650
- Condition identifier
- EFO_0000701
- Condition identifier
- EFO_0000771
- Condition identifier
- EFO_0003102
- Condition identifier
- EFO_0003106
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003894
- Condition identifier
- EFO_0003917
- Condition identifier
- EFO_0004234
- Highest recorded phase
- 1
- Condition identifier
- EFO_0005203
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005204
- Highest recorded phase
- 2
- Condition identifier
- EFO_0007205
- Highest recorded phase
- 3
- Condition identifier
- EFO_0009948
- Highest recorded phase
- 3
- Condition identifier
- EFO_0010282
- Highest recorded phase
- 3
- Condition identifier
- EFO_0011048
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000024
- Condition identifier
- EFO_1000690
- Highest recorded phase
- 3
- Condition identifier
- EFO_1000948
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001888
- Condition identifier
- EFO_1001888
- Highest recorded phase
- 4
- Condition identifier
- HP_0002014
- Highest recorded phase
- 3
And 32 more, listed on the interactive page.
- Event
- abdominal discomfort
- Reports
- 95
- Reporting signal score
- 50.7411
- Event
- acute generalised exanthematous pustulosis
- Reports
- 39
- Reporting signal score
- 58.1895
- Event
- anaphylactic reaction
- Reports
- 88
- Reporting signal score
- 65.4646
- Event
- beta haemolytic streptococcal infection
- Reports
- 18
- Reporting signal score
- 52.2302
- Event
- bloody discharge
- Reports
- 26
- Reporting signal score
- 96.4565
- Event
- chorioamnionitis
- Reports
- 12
- Reporting signal score
- 47.0208
- Event
- drug hypersensitivity
- Reports
- 2,443
- Reporting signal score
- 7,170.01
- Event
- drug interaction
- Reports
- 192
- Reporting signal score
- 102.025
- Event
- drug intolerance
- Reports
- 121
- Reporting signal score
- 81.6389
- Event
- faecal volume decreased
- Reports
- 13
- Reporting signal score
- 55.5464
- Event
- injection site pain
- Reports
- 1
- Reporting signal score
- 50.6638
- Event
- international normalised ratio fluctuation
- Reports
- 56
- Reporting signal score
- 202.549
- Event
- lyme disease
- Reports
- 24
- Reporting signal score
- 59.6348
- Event
- necrosis ischaemic
- Reports
- 17
- Reporting signal score
- 63.6926
- Event
- ototoxicity
- Reports
- 25
- Reporting signal score
- 62.9537
- Event
- pneumonia streptococcal
- Reports
- 20
- Reporting signal score
- 62.5231
- Event
- product packaging issue
- Reports
- 24
- Reporting signal score
- 51.0676
- Event
- purpura senile
- Reports
- 10
- Reporting signal score
- 48.114
- Event
- vomiting
- Reports
- 237
- Reporting signal score
- 49.5619
- NCT00000120
- NCT01946256
- NCT00002194
- NCT00021671
- NCT00147667
- NCT06395610
- NCT00259220
- NCT01716572
- NCT00304187
- NCT00648726
- NCT00718315
- NCT00770042
- NCT01117376
- NCT01323582
- NCT01309438
- NCT01323257
- NCT01340235
- NCT01659619
- NCT01668498
- NCT02099240
- NCT02381080
- Dose
- 15-20 mg/kg/day
- Route
- Intravenous
- How often
- Every 6 hours for 3 days, then every 6 hours for 7 days (oral) or as specified for other conditions
- Administer as an infusion over 20 to 60 minutes
- Discard unused portion after preparation
- Do not administer as IV push
- Hydrogen bond acceptors
- 14
- Hydrogen bond donors
- 5
- Polar surface area
- 193.91
- Calculated partition coefficient (ALogP)
- 1.79
- Calculated partition coefficient (XLogP)
- 2.7
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 7
- Heavy atoms
- 51
- Molecular formula
- C37H67NO13
- Monoisotopic mass
- 733.46124119
- Natural product
- Yes
- 0093-5571
- 0093-5572
- 13668-586
- 13668-587
- 13668-588
- 13668-606
- 13668-607
- 24208-910
- 24338-102
- 24338-104
- 24338-120
- 24338-122
- 24338-124
- 24338-126
- 45802-038
- 45802-962
- 45802-966
- 46708-397
- 46708-398
- 48102-057
- 51407-853
- 51407-854
- 51407-855
- 51407-856
- 52536-103
And 53 more, listed on the interactive page.
- Recorded assays
- 6,904
- Active assays
- 547
- Confirmatory
- Other
- Screening
- Anti-Bacterial Agents
- Gastrointestinal Agents
- Protein Synthesis Inhibitors
These details could not be displayed.
Related records
Trials (322)
- "Normal Coronary Artery" With Slow Flow Improved by Adenosine Injection, Dipyridamole Treatment and Clinical Follow-up
- "The Effect of The Combination Therapy of Statin and SGLT2i in The Treatment of Ischemic Heart Disease"
- A Multicenter, Prospective, Randomized Controlled Trial to Evaluate the Efficacy of PCSK-9 Inhibitors in Delaying the Progression of Calcified Aortic Valve Disease
- A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins
- A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses
- A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals
- A Phase II Study of DMP 115 to Assess Focal Liver Lesions
- A Project to Improve the Diagnosis and Prognosis of Myocardial Injury Associated to Non Cardiac Surgery
- A Study for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
- A Study in Healthy People to Test Whether Erythromycin Influences the Amount of BI 1291583 in the Blood
- A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
- A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function
- A Study of LY3015014 in Participants With High Cholesterol
- A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in Participants With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors (P02173)
- A Study of the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix in Healthy Adult Men
- A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults
- A Study of the Safety, Tolerability and Pharmacokinetics of Orally-administered GC4702 in Healthy Volunteers
- A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
- A Study to Evaluate the Efficacy and Safety of Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Participants (MK-0653A-406)
- A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)
Approved for (4)
- Acne
- Bacterial infectious disease
- Eye infectious disorder
- Pertussis
In development for (17)
- B-cell chronic lymphocytic leukemia Phase 1
- Bulimia nervosa Phase 2
- Chlamydia trachomatis infectious disease Phase 3
- Chronic obstructive pulmonary disease Phase 2
- Colorectal adenocarcinoma Phase 2
- Eating disorder Phase 2
- Epidermolysis bullosa Phase 3
- Erectile dysfunction Phase 1
- Gastric cancer Phase 2
- Gastroparesis Phase 2
- Hepatitis C virus infection Phase 1
- HIV infectious disease Phase 3
- Kidney failure Phase 1
- Non-small cell lung carcinoma Phase 3
- Osteomyelitis Early phase 1
- Pneumonia Phase 3
- Preterm premature rupture of the membranes Phase 3
Other linked conditions (4)
- Bronchiectasis
- Chronic rhinosinusitis
- Gram-positive bacterial infections
- Skin disorder